Azathioprine ๐
โ ๏ธ Important: Screen for thiopurine methyltransferase (TPMT) deficiency before starting therapy.
TPMT is an enzyme that metabolises azathioprine - about 1 in 300 patients have very low activity, predisposing to severe toxicity.
Patients should be warned to report immediately any signs of bone marrow suppression (e.g. unexplained bruising, bleeding, sore throat, infection).
๐ About
- Azathioprine is an immunosuppressive drug that inhibits purine metabolism, thereby suppressing DNA synthesis in proliferating cells.
- Used in autoimmune diseases (e.g. IBD, lupus, myasthenia gravis) and in transplant medicine to prevent rejection.
- Prodrug converted to 6-mercaptopurine (6-MP).
โ๏ธ Mechanism
- Azathioprine โ 6-MP โ active metabolites (e.g. 6-thioguanine nucleotides).
- Incorporated into DNA โ inhibits lymphocyte proliferation (mainly T cells).
- Blocks cell-mediated immunity and reduces antibody responses.
๐ Indications & Dosing โ Azathioprine (verify with BNF/datasheet & local guidance)
| Indication |
Details |
| ๐ฉบ Transplant rejection prophylaxis |
โข 1โ2.5 mg/kg/day PO
โข Adjust to response/tolerability
|
| ๐งฌ Autoimmune diseases |
โข 1โ3 mg/kg/day PO
โข Withdraw if no response after 3 months
|
| ๐ฉ Inflammatory bowel disease (IBD) |
โข 2โ2.5 mg/kg/day PO (normal TPMT activity)
โข โ ๏ธ Start at ~50% target dose for first week to reduce side effects
|
| ๐ IV Azathioprine |
โข Strongly irritant
โข Only if oral route not feasible
|
โ ๏ธ Side Effects
- Bone marrow suppression: leukopenia, anaemia, thrombocytopenia.
- Hypersensitivity: malaise, arthralgia, rash, fever, dizziness.
- GI/hepatobiliary: nausea, pancreatitis, hepatitis, cholestasis.
- Renal/hepatic toxicity: requires regular monitoring.
- High-dose/IV use โ severe local irritation if extravasation.
- Long-term: โ risk of non-melanoma skin cancer and lymphoma (especially with other immunosuppressants).
โ ๏ธ Cautions & Monitoring
- FBC: weekly for 4โ8 weeks, then every 1โ3 months once stable.
- LFTs & U&E: baseline and regular during treatment.
- TPMT deficiency:
- Complete deficiency = contraindication.
- Intermediate deficiency = reduce dose and monitor closely (specialist input required).
- Infection risk: avoid live vaccines; screen for hepatitis B/C, HIV, varicella, TB if clinically indicated.
๐ Interactions
- Allopurinol/febuxostat: potent xanthine oxidase inhibitors โ dangerously โ azathioprine levels โ must reduce azathioprine dose to 25โ33% if unavoidable.
- ACE inhibitors & ARBs: risk of severe haematological toxicity.
- Trimethoprim/co-trimoxazole: risk of additive bone marrow suppression.
- Rifampicin: โ efficacy by โ metabolism of 6-MP.
๐ซ Contraindications
- Complete TPMT deficiency.
- Hypersensitivity to azathioprine or 6-MP.
- Severe uncontrolled infections (bacterial, viral, e.g. varicella, HSV, shingles).
- Pregnancy: may be used with caution in some cases under specialist advice (risk vs benefit in transplant/IBD).
๐ References